Physician profile
Nicole Clark
NPI 1689861528
$85,144.19
in general payments reported to CMS, 2019-2025
31 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $8,631 · 2021: $5,454 · 2022: $20K · 2023: $21K · 2024: $2,108 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Consulting Fee: $9,510 · Travel and Lodging: $8,598 · Food and Beverage: $2,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,391.00 |
| Consulting Fee | $9,510.00 |
| Travel and Lodging | $8,597.90 |
| Food and Beverage | $2,598.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $40,410.51 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Janssen Biotech, INC. | $16,801.23 | 2025 | |
| Allergan, INC. | $9,692.44 | 2019-2021 | |
| Amgen INC. | $7,547.34 | 2020-2025 | Uplizna |
| Janssen Scientific Affairs, LLC | $1,857.16 | 2024-2025 | |
| Abbvie INC. | $1,793.66 | 2021-2023 | Qulipta |
| Lundbeck LLC | $1,275.00 | 2025 | Vyepti |
| Genzyme Corporation | $1,251.58 | 2019-2023 | |
| Boston Scientific Corporation | $1,139.71 | 2019-2025 | Vercise |
| Biohaven Pharmaceuticals, INC. | $1,125.00 | 2020 | |
| Biogen, INC. | $376.73 | 2019-2024 | Vumerity |
| Livanova USA, INC. | $283.50 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Teva Pharmaceuticals USA, INC. | $273.50 | 2019-2025 | Austedo Xr |
| Celgene Corporation | $271.50 | 2019-2024 | Zeposia |
| Emd Serono, INC. | $224.48 | 2020-2025 | Mavenclad |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $215.79 | 2019-2024 | Ocrevus, Enspryng |
| Neurocrine Biosciences, INC. | $165.54 | 2019-2021 | |
| Pfizer INC. | $113.25 | 2019-2025 | |
| Tg Therapeutics, INC. | $48.31 | 2025 | |
| Lilly USA, LLC | $48.17 | 2019-2020 | |
| Ucb, INC. | $41.55 | 2019 | |
| Jazz Pharmaceuticals INC. | $27.94 | 2023 | Epidiolex |
| Sunovion Pharmaceuticals INC. | $25.13 | 2019 | |
| Abbott Laboratories | $22.11 | 2020 | |
| Acorda Therapeutics, INC | $21.22 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $19.59 | 2023 | Firdapse |
| Alexion Pharmaceuticals, INC. | $17.70 | 2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $14.53 | 2020 | |
| Merz Pharmaceuticals, LLC | $14.45 | 2022 | |
| Medtronic USA, INC. | $12.88 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.